1 / 5

Time to Recurrence (Hormone Receptor-positive Patients)

Time to Recurrence (Hormone Receptor-positive Patients). Tamoxifen (T) Anastrozole (A). At risk : A T. 2618 2598. 2541 2516. 2453 2400. 2361 2306. 2278 2196. 2159 2075. 1995 1896. 1801 1711. 1492 1396. 608 547. 30. HR 0.76. 95% CI (0.67, 0.87). P -value 0.0001. 25. HR+. 21.8%.

sylvester-duffy
Download Presentation

Time to Recurrence (Hormone Receptor-positive Patients)

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Time to Recurrence(Hormone Receptor-positive Patients) Tamoxifen (T) Anastrozole (A) Atrisk:AT 26182598 25412516 24532400 23612306 22782196 21592075 19951896 18011711 14921396 608547 30 HR 0.76 95% CI (0.67, 0.87) P-value 0.0001 25 HR+ 21.8% 20 Patients (%) 15 12.5% 17.0% 10 9.7% 5 Absolutedifference 2.8% 4.8% 0 0 1 2 3 4 5 6 7 8 9 Follow-up time (years) HR=hazard ratio; HR+=hormone receptor-positive; CI=confidence interval Adapted from Forbes J. SABCS 2007.

  2. At risk:AT 26182598 25412516 24532400 23612306 22782196 21592075 19951896 18011711 14921396 608547 Disease-free Survival (Hormone Receptor-positive Patients) 29.9% 30 HR 0.85 95% CI (0.76, 0.94) P-value 0.003 HR+ 25 25.8% 20 Tamoxifen (T) Anastrozole (A) 16.4% 15 Patients (%) 10 13.9% 5 Absolute difference 2.5% 4.1% 0 0 1 2 3 4 5 6 7 8 9 Follow-up time (years) HR=hazard ratio; HR+=hormone receptor-positive; CI=confidence interval Adapted from Forbes J. SABCS 2007.

  3. Tamoxifen (T) Anastrozole (A) Time to Recurrence: Smoothed Hazard Estimates (Hormone Receptor-positive Patients) 4.0 3.0 Annual hazard rates (%) 2.0 1.0 0.0 0 1 2 3 4 5 6 7 8 9 Follow-up time (years) Adapted from Forbes J. SABCS 2007.

  4. Fracture Episode Rates Throughout the Study 4 Tamoxifen (T) Anastrozole (A) 3 2 Annual fracture episode rates (%) 1 0 0 1 2 3 4 5 6 7 8 9 Time since randomization (years) At risk: A T 2984 2976 2859 2824 2745 2699 2640 2572 2496 2419 2306 2208 2077 2000 1713 1645 702 659 Adapted from Forbes J. SABCS 2007.

  5. Benefits Continue and Detrimental Effects Decline After Treatment Cessation Time to recurrence Fracture episode rates 4 30 Tamoxifen (T) Anastrozole (A) Tamoxifen (T) Anastrozole (A) 25 21.8% 3 20 Patients (%) Annual fracture episode rates (%) 2 15 12.5% 17.0% 10 1 9.7% 5 Absolutedifference 2.8% 4.8% 0 0 0 1 2 3 4 5 6 7 8 9 0 1 2 3 4 5 6 7 8 9 Follow-up time (years) Time since randomization (years) Adapted from Forbes J. SABCS 2007.

More Related